Sprionaloctone

Description

NHS England has published this Preliminary Market Engagement Notice for the Licence variation: spironolactone for acne in women. It is anticipated that there will be two separate contracts to deliver this, as outlined below. • Contract A: Prepare an application for a major (type II) MHRA Marketing Authorisation variation for spironolactone. • Contract B: Submit the pre-prepared application to the MHRA. Only current Marketing Authorisation Holders of spironolactone are eligible to bid for contract B. To register an interest in responding to this market engagement exercise and obtain a copy of the Request for Information documentation please go to: http://health.atamis.co.uk. All communications and Request for Information submissions will be conducted via Atamis.